Paper Details

  1. Home
  2. Paper Details

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

Author: AbdelnourArturo, AcuñaTeobaldo Herrera, AragónCarlos Fernándo Grazioso, CastrejónTirza De León, ChiuCheng-Hsun, ChiuNan-Chang, DullPeter M, HohenbokenMatthew, IzuAllen, LamasMarta Raquel Valdés, OdrljinTatjana, SilasPeter E, SmolenovIgor

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase 3b study evaluated the safety of a 4-dose series of MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, in healthy infants. The vaccine was administered concomitantly with routine vaccinations.
Paper Details　
Original Abstract of the Article :
The highest risk for invasive meningococcal disease (IMD) is in infants aged <1 year. Quadrivalent meningococcal conjugate vaccination has the potential to prevent IMD caused by serogroups A, C, W and Y. This phase 3b, multinational, open-label, randomized, parallel-group, multicenter study evaluate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2013.12.034

データ提供：米国国立医学図書館（NLM）

A Safe Haven for Infants: Meningococcal Vaccination and Routine Immunizations

The health and well-being of infants are paramount, and protecting them from infectious diseases is a top priority. This study delves into the safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) when administered with routine infant vaccinations. It's a crucial undertaking, like ensuring the safety and security of a caravan traveling through the desert.

The Safety of MenACWY-CRM: A Path Paved with Research

The study findings demonstrate that the MenACWY-CRM vaccine, when administered with routine vaccinations, is safe for infants. This is a significant step forward in protecting infants from invasive meningococcal disease, a potentially life-threatening condition. It's like finding a reliable oasis in the midst of a vast and unforgiving desert.

A Protective Shield for Little Travelers: A Safe Journey Through Childhood

This research provides valuable insights into the safety and efficacy of MenACWY-CRM vaccination in infants. It offers reassurance to parents and healthcare providers alike, highlighting the importance of vaccination in safeguarding the health of our youngest and most vulnerable members of society.

Dr.Camel's Conclusion

This study provides strong evidence for the safety and efficacy of MenACWY-CRM vaccination in infants. It's like a guiding beacon for parents, illuminating the path towards a healthier and safer future for their children. By ensuring that infants receive the appropriate vaccinations, we can create a more secure and protected world for them to thrive.

Date :
  1. Date Completed 2014-08-15
  2. Date Revised 2014-01-31
Further Info :

Pubmed ID

24397906

DOI: Digital Object Identifier

10.1016/j.vaccine.2013.12.034

Related Literature

Article Analysis
・Side Effects of polio vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.